News articles about Cardiome Pharma (NASDAQ:CRME) (TSE:COM) have trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cardiome Pharma earned a daily sentiment score of 0.17 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 47.3266332600113 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Shares of Cardiome Pharma (NASDAQ:CRME) traded up $0.34 during trading hours on Tuesday, reaching $1.91. The company’s stock had a trading volume of 4,655,995 shares, compared to its average volume of 144,792. The stock has a market capitalization of $55.42, a PE ratio of -2.13 and a beta of 0.65. The company has a debt-to-equity ratio of 1.67, a current ratio of 5.52 and a quick ratio of 4.71. Cardiome Pharma has a fifty-two week low of $1.29 and a fifty-two week high of $4.84.
CRME has been the subject of several analyst reports. Mackie upgraded Cardiome Pharma to a “buy” rating in a report on Friday, December 15th. HC Wainwright reaffirmed a “buy” rating and set a $9.50 price objective on shares of Cardiome Pharma in a research report on Wednesday, November 22nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. Cardiome Pharma currently has a consensus rating of “Hold” and an average target price of $5.50.
Cardiome Pharma Company Profile
Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome.
Receive News & Ratings for Cardiome Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiome Pharma and related companies with MarketBeat.com's FREE daily email newsletter.